(Q28377244)

https://api.crossref.org/works/10.1016%2FS0006-2952%2899%2900073-8

Long-term efficacy of active postexposure immunization of infants for prevention of hepatitis B virus infection. United States-People's Republic of China Study Group on Hepatitis B.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2899%2900073-8

Effect of Alpha-Interferon Treatment in Patients with Hepatitis B e Antigen-Positive Chronic Hepatitis B

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2899%2900073-8

A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. The Hepatitis Interventional Therapy Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2899%2900073-8

Treatment of chronic hepatitis B with interferon: experience in western countries

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2899%2900073-8

Inhibition of the replication of hepatitis B virus in vitro by 2',3'-dideoxy-3'-thiacytidine and related analogues

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2899%2900073-8

A preliminary trial of lamivudine for chronic hepatitis B infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2899%2900073-8

Therapy of viral hepatitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2899%2900073-8

Role of additional mutations outside the YMDD motif of hepatitis B virus polymerase in L(-)SddC (3TC) resistance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2899%2900073-8

A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. AIDS Clinical Trials Group Study 175 Study Team

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2899%2900073-8

Two-Drug Combinations of Zidovudine, Didanosine, and Recombinant Interferon- A Inhibit Replication of Zidovudine-Resistant Human Immunodeficiency Virus Type 1 Synergistically In Vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2899%2900073-8

Inhibitory effect of 9-(2-phosphonylmethoxyethyl)-adenine (PMEA) on human and duck hepatitis B virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2899%2900073-8

Penciclovir is a selective inhibitor of hepatitis B virus replication in cultured human hepatoblastoma cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2899%2900073-8

Inhibition of hepatitis B virus DNA polymerase by enantiomers of penciclovir triphosphate and metabolic basis for selective inhibition of HBV replication by penciclovir

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2899%2900073-8

Effects of purine nucleoside analogues with a cyclobutane ring and erythromycin A oxime derivatives on duck hepatitis B virus replication in vivo and in cell culture and HIV-1 in cell culture

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2899%2900073-8

Hepatitis B virus polymerase mutations during antiviral therapy in a patient following liver transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2899%2900073-8

Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2899%2900073-8

Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2899%2900073-8

Design and synthesis of 2',3'-dideoxy-2',3'-didehydro-beta-L-cytidine (beta-L-d4C) and 2',3'-dideoxy 2',3'-didehydro-beta-L-5-fluorocytidine (beta-L-Fd4C), two exceptionally potent inhibitors of human hepatitis B virus (HBV) and potent inhibitors of

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2899%2900073-8

Use of 2'-fluoro-5-methyl-beta-L-arabinofuranosyluracil as a novel antiviral agent for hepatitis B virus and Epstein-Barr virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2899%2900073-8

Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2899%2900073-8

Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2899%2900073-8

Transient selection of a hepatitis B virus polymerase gene mutant associated with a decreased replication capacity and famciclovir resistance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2899%2900073-8

Anti-human immunodeficiency virus (HIV) activity, safety, and pharmacokinetics of adefovir dipivoxil (9-[2-(bis-pivaloyloxymethyl)-phosphonylmethoxyethyl]adenine) in HIV-infected patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2899%2900073-8

Inhibition of hepatitis B virus by a novel L-nucleoside, 2'-fluoro-5-methyl-beta-L-arabinofuranosyl uracil

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2899%2900073-8

inferred from DOI database lookup

7 January 2021

based on heuristic

Unique metabolism of a novel antiviral L-nucleoside analog, 2'-fluoro-5-methyl-beta-L-arabinofuranosyluracil: a substrate for both thymidine kinase and deoxycytidine kinase

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2899%2900073-8